XERS — Xeris Biopharma Holdings Share News
0.000.00%
Last trade - 00:00- $1.84bn
- $1.97bn
- $291.85m
Brief: Xeris Biopharma Says FDA Grants Orphan-Drug Exclusivity For Recorlev
Brief: Xeris Expects To End 2022 With Over $120 Mln In Cash, Cash Equivalents & Short-Term Investments
Brief: Xeris Biopharma Announces Plans For A Phase Ii Dose-Finding Study For Its Investigational Subcutaneous (SC) Levothyroxine (Xp-8121) As Replacement Therapy For Hypothyroidism
U.S. STOCKS ON THE MOVE-Uniqure, BioMarin, Blueprint Medicines
U.S. STOCKS ON THE MOVE-Manchester United, Tesla, Deere
U.S. STOCKS ON THE MOVE-HP Inc, Xeris, Tesla
Xeris jumps on eye injection development tie-up with Horizon
Brief: Xeris Biopharma Announces Research Collaboration And Option Agreement With Horizon Therapeutics PLC For Xeriject™ Formulation Of Teprotumumab
Brief: Xeris Biopharma Reports Third Quarter 2022 Financial Results And Recent Events
Brief: Xeris Biopharma Announces Results Of The Extended Evaluation Of Recorlev From Phase 3 Sonics Study
U.S. STOCKS ON THE MOVE-Lam Research, Cyngn, Par Pacific
U.S. STOCKS ON THE MOVE-Vertiv, U.S. energy, Gold miners
U.S. STOCKS ON THE MOVE-AT&T, Blackstone, HOOKIPA Pharma
U.S. STOCKS ON THE MOVE-Tesla, Xeris Biopharma
Xeris Biopharma up on positive data from thyroid drug trial
Brief: Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data Of Its Investigational Subcutaneous (SC) Levothyroxine (Xp-8121) Hosts Conference Call And Webcast
U.S. STOCKS ON THE MOVE-Mega-cap growth stocks, U.S. restaurants
U.S. STOCKS ON THE MOVE-Retail stocks, payment firms, travel stocks
U.S. STOCKS ON THE MOVE-Twitter, Nikola, Tesla, Xeris Biopharma